CURRENT ISSUES OF ANTIVIRAL THERAPY OF ARVI AND INFLUENZA IN MILITARY UNITS

Conducting preventive medical and epidemiological measures for influenza and ARVI in closed military units, including on ships, vessels and auxiliary units of the Navy, is a factor of increasing the combat effectiveness of forces of the Russian Army. In the structure of total morbidity of military personnel, acute respiratory viral infections account for 35–50%, however, during the young military reinforcement, the incidence of these infections in combination with community-acquired pneumonia can reach 70–80%. The risk of exceeding the epidemiological threshold for respiratory tract infections, the etiological basis of which is viral aggression, is especially important in newly formed military contingents, for units participating in local military conflicts and peacekeeping operations, as well as with a new recruitment of cadets at training centers. The use of non-specific antiviral drugs based on exogenous recombinant interferon -2b is one of the conditions for adequate prevention of influenza and ARVI in closed military units. The paper presents the results from the analysis of publications on the effectiveness and Viferon® safety in the treatment of influenza and ARVI. Viferon is a preparation of recombinant human interferon -2b with a complex of antioxidants in various dosage forms, used in the treatment and prevention of acute respiratory viral infections and influenza. Use of Viferon in various dosage forms is a reliable method of prevention and treatment of influenza and other acute respiratory viral infections in military forces, including on ships, vessels and auxiliary units of the Navy, at risk of emergency epidemiological situations due to ARVI and influenza, in conditions of limited contingent.

marine medicine, influenza, ARVI (acute respiratory viral infections), prevention, interferons, military units, Viferon, antiviral immunity, review

1. Akimkin V.G., Korotchenko S.I., Shevtsov V.A., Volgin A.R., Salmina T.A., Kalabukhova L.Yu., Malinovskaya V.V., Gatich R.Z., Semenenko T.A., Guseva T.S., Parshina O.V., Dmitrieva E.V. Epidemiological and immunological effectiveness of the use of the drug Viferon, a gel for the prevention of influenza and other acute respiratory infections in organized military collectives. Epidemiologya i aktualnye voprosy, 2011, No. 1, рp. 28–36 (In Russ.).

2. Yershov F.I., Kiselev O.I. Interferons and their inductors (from molecules to drugs). Moscow: Publishing house GEOTAR-Media, 2005, 356 р. (In Russ.).

3. Afanasiev S.S., Onishchenko G.G., Aleshkin V.A., Afanasiev М.S. Interferon status, interferon preparations in the treatment and prevention of infectious diseases and re-habilitation of patients. Moscow: Publishing house TriadаX, 2005. 768 p. (In Russ.).

4. Kalyuzhin O.V. Acute respiratory viral infections: modern challenges, antiviral response, immunoprophylaxis and immunotherapy. Moscow: Publishing house MIA, 2014, 144 р. (In Russ.).

5. Mordstein M., Neugebauer E., Ditt V. Lambda interferon renders epithelial cells of the respiratory and gastro-intestinal tracts resistant to viral infections // J. Virol. 2010. Vol. 84, No. 11. P. 5670–5677.

6. Totolyan A.A., Freidlin I.S. cells of the immune system. Saint Petersburg: Publishing house Nauka, 2000, 233 р. (In Russ.).

7. Karaulov A.V., Kalyuzhin O.V. Cytokines: biological action and clinical application. Advances in clinical immunology and Allergology / ed. A.V. Karaulov. Vol. 1. Moscow: Publishing house the Academy of Natural Sciences, 2000, рр. 193–205 (In Russ.).

8. Kalyuzhin O.V., Ponezheva Zh.B., Semenova I.V., Hohlova O.N., Serebryakovskaya L.V., Guseva T.S., Parshina O.V., Maleev V.V. lymphocyte Subpopulations, interferon level and expression of their receptors in patients with chronic hepatitis B and C: dependence on the type of viruses and the degree of fibrosis. Therapeutic archive, 2017, Vol. 89, No. 11, рр. 14–20 (In Russ.).

9. Ponezheva Zh.B., Kupchenko A.N., Mannanova I.V., Gorelov A.V. Interferons and antiviral immunity. Effective pharmacotherapy, 2018, No 14, рp. 14–20 (In Russ.).

10. García-Sastre A. Induction and evasion of type I interferon responses by influenza viruses // Virus Res. 2011. Vol. 162, No. 1–2. P. 12–18.

11. Van de Sandt C.E., Kreijtz J.H., Rimmelzwaan G.F. Evasion of influenza A viruses from innate and adaptive immune responses // Viruses. 2012. Vol. 4, No. 9. P. 1438–1476.

12. Swedan S., Andrews J., Majumdar T., Musiyenko A., Barik S. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location // J. Virol. 2011. Vol. 85, No. 19. P. 10090–10100.

13. Le Page C., Génin P., Baines M.G., Hiscott J. Interferon activation and innate immunity // Rev. Immunogenet. 2000. Vol. 2, No. 3. P. 374–386.

14. Levin S., Hahn T. Evaluation of the human interferon system in viral disease // Clin. Exp. Immunol. 1981. Vol. 46, No. 3. P. 475–483.

15. Nesterova I.V. Congenital and acquired interferonbeta: differentiated approaches to interferon corrective therapy. Children’s infections, 2017, Vol. 16, No. 2, рр. 50–53 (In Russ.).

16. Schomacker H., Hebner R.M., Boonyaratanakornkit J., Surman S., Amaro-Carambot E., Collins P.L., Schmidt A.C. The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome // PLoS One. 2012. Vol. 7, No. 2. P. e28382.

17. Malinovskaya V.V., Gevorkyan M.G., Borchsh-Kompaniets S.F., Kostyukova N.N. Recombinant interferon in treatment of infectious diseases of central nervous system in newborns // Immunotherapeutic prospects of infectious diseases. Berlin, Heidelberg: Springer-Verlag, 1990. P. 285–286.

18. Kolobukhina L.V., Merkulova L.N., Malyshev N.A., Shchelkanov M.Yu., Isaeva E.I., Shestakova O.M., Gatich R.Z., Guseva T.S., Parshina O.V., Malinovskaya V.V. Possibilities of local interferonotherapy of flu complicated by angina. RMZH, 2010, Vol. 18, No. 24, рp. 1462–1466 (In Russ.).

19. Chen W., Calvo P.A., Malide D., Gibbs J., Schubert U., Bacik I. A novel influenza A virus mitochondrial protein that induces cell death // Nat. Med. 2001. Vol. 7. P. 1306–1312.

20. Maleeva L.I., Sergeev V.V., Pechenkina S.I., Kuznetsov V.P. The effect of interferon on increasing the sensitivity of bacteria to antibiotics. Antibiotics and chemotherapy, 1988, No. 11, pp. 820–823 (In Russ.).

21. Simbirtsev A.S. Clinical application of cytokine preparations. Immunology, 2004, Vol. 25, No. 4, рр. 247–251 (In Russ.).

22. Ponezheva Zh.B., Kupchenko A.N., Ponezheva L.O., Guseva T.S., Parshina O.V., Malinovskaya V.V., Karaulov A.V. Clinical and immunological efficacy of a combination of rectal and intranasal forms of recombinant interferon Alfa-2b in the treatment of acute respiratory viral infections. RMJ. Medical review, 2018, No. 8 (II), pp. 62–66 (In Russ.).

23. Malinovskaya V.V., Chebotareva T.A., Parfenov V.V. Clinical efficacy of the drug Viferon in the treatment of influenza and SARS in adults. Almanac of clinical medicine, 2014, No. 35, рp. 109–115 (In Russ.).

24. Vasiliev A.N., Gatich R.Z., Kolobukhina L.V., Isaeva E.I., Burtseva E.I., Orlova T.G., Voronina F.V., Malinovskaya V.V. Effectiveness of VIFERON in influenza in adult patients. Antibiotics and chemotherapy, 2009, No. 54, рp. 21–24 (In Russ.).

25. Tyutyunnikov S.V., Antonov Yu.A., Kuzyakin G.V. Topical application of recombinant interferon alpha in patients with influenza a (H1N1) pdm09. Bulletin of clinical medicine, 2015, Vol. 6, рp. 24–30 (In Russ.).